KRT80: A Potential Drug Target and Biomarker (G144501)

Target Name: KRT80

NCBI ID: G144501

KRT80

KRT80: A Potential Drug Target and Biomarker

Keratin is a protein that is found in the hair, nails, and skin. It is an essential component of these tissues, and it plays a crucial role in their growth and maintenance. One of the different types of keratin is KRT80, which has been identified as a potential drug target and biomarker.

KRT80 is a type II keratin protein that is expressed in high levels in the scalp and hair follicles. It is composed of 18 distinct protein chains, each of which is responsible for different functions in the hair growth and development process. One of the unique features of KRT80 is its ability to form a stable complex with the protein tyrosine hydroxylase (PHD), which is a key enzyme involved in the production of dopamine.

The tyrosine hydroxylase enzyme is known for its role in the production of dopamine, which is a neurotransmitter that is involved in various brain functions, including motivation, pleasure, and movement. It is also involved in the development and maintenance of the hair, as higher levels of dopamine have been shown to promote hair growth and development.

Research has suggested that KRT80 may be a useful drug target for the treatment of various conditions that are characterized by hair loss or dysfunction. These conditions include male pattern baldness, female pattern baldness, and androgen-dependent alopecia.

In male pattern baldness, the underlying cause is a genetic mutation that leads to the production of excessively active tyrosine hydroxylase. This can lead to the rapid growth of hair follicles, which can cause the hair to become weak and breakable. By inhibiting the activity of the tyrosine hydroxylase enzyme, it is possible to slow down or even reverse the growth of hair follicles and reduce the risk of hair loss.

In female pattern baldness, the underlying cause is not well understood, but it is thought to be related to changes in the levels of estrogen. Estrogen is involved in the development and maintenance of hair, and higher levels of estrogen have been shown to promote hair growth in some women. However, in women with female pattern baldness, the levels of estrogen are lower than in men, which may contribute to the condition.

KRT80 has also been shown to be a potential biomarker for the diagnosis of androgen-dependent alopecia. This condition is characterized by a progressive loss of hair, and it is often associated with high levels of androgens, such as testosterone.

The ability of KRT80 to form a stable complex with the tyrosine hydroxylase enzyme makes it a promising candidate for the treatment of hair loss and dysfunction. Studies have shown that topical treatments that contain KRT80 can significantly improve the growth and thickness of the hair, and they may also reduce the risk of hair loss.

In conclusion, KRT80 is a unique protein that is expressed in high levels in the hair and has been shown to play a crucial role in the growth and development of hair. Its ability to form a stable complex with the tyrosine hydroxylase enzyme makes it a potential drug target for the treatment of hair loss and dysfunction. Further research is needed to fully understand the role of KRT80 in these conditions and to develop safe and effective treatments.

Protein Name: Keratin 80

The "KRT80 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT80 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets